Procept Biorobotics Corp (PRCT)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.37B
Last updated: Nov 17, 2026 at 11:06 AM ET
Procept Biorobotics Corp (PRCT) Earnings: Report Dates and Results
Procept Biorobotics (PRCT) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Procept Biorobotics reported EPS of -$0.46, below the -$0.39 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PRCT has an expected report date of Feb 23, 2027.
PRCT Earnings Call
The latest PRCT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 22 quarters below that had an estimate, PRCT beat 11, missed 9 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $98.29M, up 18.0% from $83.33M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.46 | -$0.39 | -$0.42 - -$0.34 | -17.95% | Miss | N/A | 11 | 0 up, 9 down | Nov 4, 2026 | $98.29M |
| Jun 30, 2026 | -$0.47 | -$0.46 | -$0.51 - -$0.36 | -2.17% | Miss | N/A | 10 | 1 up, 1 down | Aug 4, 2026 | $94.50M |
| Mar 31, 2026 | -$0.56 | -$0.56 | -$0.61 - -$0.48 | 0.00% | In line | N/A | 10 | 0 up, 8 down | Apr 29, 2026 | $83.13M |
| Dec 31, 2025 | -$0.53 | -$0.32 | -$0.35 - -$0.28 | -63.43% | Miss | N/A | 9 | 0 up, 3 down | Feb 25, 2026 | $76.38M |
| Sep 30, 2025 | -$0.38 | -$0.42 | -$0.45 - -$0.38 | +9.52% | Beat | N/A | 9 | 1 up, 7 down | Nov 4, 2025 | $83.33M |
| Jun 30, 2025 | -$0.35 | -$0.41 | -$0.49 - -$0.31 | +14.63% | Beat | N/A | 10 | 1 up, 0 down | Aug 6, 2025 | $79.18M |
| Mar 31, 2025 | -$0.45 | -$0.49 | -$0.51 - -$0.47 | +8.16% | Beat | N/A | 8 | 0 up, 4 down | Apr 24, 2025 | $69.16M |
| Dec 31, 2024 | -$0.35 | -$0.34 | -$0.44 - -$0.32 | -2.94% | Miss | N/A | 8 | 2 up, 0 down | Feb 25, 2025 | $68.24M |
| Sep 30, 2024 | -$0.40 | -$0.49 | -$0.51 - -$0.44 | +18.37% | Beat | N/A | 7 | 1 up, 0 down | Oct 28, 2024 | $58.37M |
| Jun 30, 2024 | -$0.50 | -$0.52 | -$0.55 - -$0.50 | +3.85% | Beat | N/A | 8 | 0 up, 0 down | Aug 1, 2024 | $53.35M |
| Mar 31, 2024 | -$0.51 | -$0.56 | -$0.61 - -$0.49 | +8.93% | Beat | N/A | 8 | 0 up, 0 down | May 1, 2024 | $44.54M |
| Dec 31, 2023 | -$0.54 | -$0.45 | -$0.50 - -$0.40 | -20.00% | Miss | N/A | 8 | 0 up, 0 down | Feb 27, 2024 | $43.58M |
| Sep 30, 2023 | -$0.51 | -$0.52 | -$0.56 - -$0.51 | +1.92% | Beat | N/A | 9 | 0 up, 0 down | Nov 1, 2023 | $35.10M |
| Jun 30, 2023 | -$0.56 | -$0.56 | -$0.62 - -$0.55 | 0.00% | In line | N/A | 8 | 0 up, 0 down | Jul 27, 2023 | $33.10M |
| Mar 31, 2023 | -$0.63 | -$0.58 | -$0.64 - -$0.54 | -8.62% | Miss | N/A | 7 | 0 up, 1 down | Apr 27, 2023 | $24.40M |
| Dec 31, 2022 | -$0.56 | -$0.54 | -$0.59 - -$0.50 | -3.70% | Miss | N/A | 7 | 0 up, 0 down | Feb 28, 2023 | $23.78M |
| Sep 30, 2022 | -$0.51 | -$0.52 | -$0.53 - -$0.42 | +1.92% | Beat | N/A | 8 | 0 up, 0 down | Nov 3, 2022 | $20.35M |
| Jun 30, 2022 | -$0.43 | -$0.48 | -$0.50 - -$0.45 | +10.42% | Beat | N/A | 5 | 0 up, 0 down | Aug 4, 2022 | $16.69M |
| Mar 31, 2022 | -$0.39 | -$0.47 | -$0.52 - -$0.43 | +17.02% | Beat | N/A | 4 | 0 up, 0 down | May 5, 2022 | $14.20M |
| Dec 31, 2021 | -$0.42 | -$0.39 | -$0.42 - -$0.37 | -7.69% | Miss | N/A | 5 | 0 up, 0 down | Mar 8, 2022 | $10.14M |
| Sep 30, 2021 | -$0.32 | -$0.42 | -$0.45 - -$0.34 | +23.81% | Beat | N/A | 4 | N/A | Nov 4, 2021 | $8.67M |
| Jun 30, 2021 | -$0.41 | -$0.40 | N/A | -2.50% | Miss | N/A | N/A | N/A | Sep 16, 2021 | $8.48M |
| Mar 31, 2021 | -$2.63 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2021 | $7.19M |
| Dec 31, 2020 | -$2.63 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2021 | $3.22M |
| Sep 30, 2020 | -$3.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2020 | $2.11M |
| Jun 30, 2020 | -$3.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2020 | $1.19M |
| Mar 31, 2020 | -$4.56 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2020 | $1.19M |
| Dec 31, 2019 | -$4.56 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.71, after -$1.76 the year before. It was -$4.56 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.71 | N/A |
| Dec 31, 2024 | -$1.76 | N/A |
| Dec 31, 2023 | -$2.24 | N/A |
| Dec 31, 2022 | -$1.89 | N/A |
| Dec 31, 2021 | -$3.78 | N/A |
| Dec 31, 2020 | -$13.24 | N/A |
| Dec 31, 2019 | -$4.56 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,400 words across 17 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,421 | 17 | |
| 2026Q2 | Jun 30, 2026 | 8,288 | 16 | |
| 2026Q1 | Mar 31, 2026 | 5,890 | 15 | |
| 2025Q4 | Dec 31, 2025 | 8,568 | 16 | |
| 2025Q3 | Sep 30, 2025 | 8,037 | 17 | |
| 2025Q2 | Jun 30, 2025 | 7,936 | 16 | |
| 2025Q1 | Mar 31, 2025 | 8,678 | 16 | |
| 2024Q4 | Dec 31, 2024 | 9,351 | 14 |
2026Q3 Earnings Call
Opening remarks
Webb Campbell Gilmartin Group Good afternoon, and thank you for joining PROCEPT BioRobotics Third Quarter 2026 Earnings Conference Call. Presenting on today's call are Larry Wood, Chief Executive Officer, and Kevin Waters, Chief Financial Officer. Before we begin, I'd like to remind listeners that statements made on this conference call that relate to future plans, events or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. While these forward-looking statements are based on management's current expectations and beliefs, these statements are subject to several risks and uncertainties, assumptions and other factors that could cause results to differ materially from the expectations expressed on this conference call. These risks and uncertainties are disclosed in more detail in PROCEPT BioRobotics' filings with the Securities and Exchange Commission, all of which are available online at sec.gov. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date, November 4, 2026. Except as required by law, PROCEPT BioRobotics undertakes no obligation to update or revise any forward-looking statements to reflect new information, circumstances or unanticipated events that may arise. During the call, we'll also reference certain financial measures that are not prepared in accordance with GAAP. More information about how we use these non-GAAP financial measures, as well as reconciliations of these measures to their nearest GAAP equivalents, are included in our earnings release. With that, I'd like to turn the call over to Larry.
Larry Wood CEO Good afternoon, and thank you for joining us. This quarter, we continued to execute against the priorities we set at the beginning of the year and delivered total revenue of $98.3 million, reflecting 18% year-over-year growth. We completed over 13,400 U.S. procedures in the quarter, growing 22% year-over-year, led by our HYDROS accounts, where we continue to see strong utilization. With our installed base actively transitioning to HYDROS and our dedicated launch team supporting new systems, we continue to strengthen our foundation for healthy utilization and growth. U.S. handpiece and consumable revenue grew over 21%, with handpieces sold at 106% of procedures, roughly consistent with our full-year projections of a 1:1 ratio and reflecting normalized field inventory. Handpiece pricing remained strong at approximately $3,570, reflecting our continued price discipline. Turning to U.S. systems, we placed 62 HYDROS systems in the quarter, including 20 replacement systems. We continue to accelerate the upgrade of legacy AQUABEAM systems to HYDROS. While the greenfield placements fell short of our expectations for Q3, this was largely a function of timing, and we are seeing healthy overall capital demand continue into the fourth quarter.
Frequently Asked Questions About PRCT
When is Procept Biorobotics's next earnings date?
Procept Biorobotics's next earnings report is expected for Feb 23, 2027.
Did PRCT beat earnings estimates last quarter?
No. Procept Biorobotics reported EPS of -$0.46 for the quarter ended Sep 30, 2026, below the -$0.39 estimate by 17.95%.
What EPS do analysts expect from PRCT next quarter?
The consensus EPS estimate for Procept Biorobotics for the quarter ending Dec 31, 2026 is -$0.25 from 17 analysts, with estimates from -$0.27 to -$0.20.
How often does PRCT beat earnings estimates?
Procept Biorobotics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -6.77%.
PRCT pages: Overview, Earnings, Forecast, Financials, Competitors